NCT04884997

A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma

An Exploratory Study of PD-1 Antibody(Toripalimab) or Combining With Temozolomide for Injection in the Treatment of Advanced/Metastatic Malignant Melanoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: First Affiliated Hospital of Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study evaluate toripalimab or combining with temozolomide for injection in the treatment of advanced/metastatic malignant melanoma. Participants in arm A receive toripalimab, in arm B receive toripalimab plus temozolomide

Conditions

• Malignant Melanoma

Interventions

Type	Name	Description
DRUG	toripalimab	toripalimab 3mg/kg, Q2w;
DRUG	Temozolomide Injection	Temozolomide 150mg/m2,d1-5,Q4w

Timeline

• Start date: 2021-03-07
• Primary completion: 2024-03-07
• Completion: 2024-09-07
• First posted: 2021-05-13
• Last updated: 2021-05-13

Locations

1 site across 1 country: China